• Explore /
  • Poster
  • / Combined inhibition of mTORC1 with temsirolimus and HER2 with neratinib: A phase I study in patients with metastatic HER2-amplified breast cancer.

Combined inhibition of mTORC1 with temsirolimus and HER2 with neratinib: A phase I study in patients with metastatic HER2-amplified breast cancer.

Abstract Poster

Authors

null

D. Gajria

Memorial Sloan-Kettering Cancer Center, New York, NY

D. Gajria , T. A. King , H. Pannu , R. Sakr , A. D. Seidman , A. Syldor , S. Patil , M. Maybody , L. Norton , N. Rosen , C. Hudis , S. Chandarlapaty

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2011 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Breast Cancer - HER2/ER

Track

Breast Cancer

Sub Track

HER2+

Clinical Trial Registration Number

NCT01111825

Citation

J Clin Oncol 29: 2011 (suppl; abstr 574)

Abstract #

574

Poster Bd #

5H

Abstract Disclosures

Similar Posters

First Author: Payal Deepak Shah

First Author: Sarika Jain

First Author: Maria Alsina

First Author: Gargi D. Basu